BioTrove, Synchron Team Up for European Customer Solutions
BioTrove Names Paul E. Cochran Senior Vice President of Human Resources
BioTrove Combines Forces with OSI Pharmaceuticals to Enable Lead Discovery
BioTrove, Inc. Announces Filing of Registration Statement for Initial Public Offering
BioTrove Names New Division Vice President-General Managers
Children’s National Medical Center to Investigate Diabetes Genetic Markers with OpenArray™ System
BioTrove Names Edward "Buzz" Sztukowski Senior Vice President and Chief Business Officer
BioTrove, Inc. CEO Albert Luderer to Present at Piper Jaffray Health Care Conference
May 18 - 21, 2008 International Society for the Study of Xenobiotics Vienna, Austria Present with Agilent Booth 70
Wednesday, May 21 @ 12.30 Seminar - Lecture Room GH Advanced pharmaceutical applications of Mass Spectrometry in Drug discovery Selena Larkin, Ph.D., BioTrove Inc.
May 31 - June 3, 2008 European Society of Human Genetics Barcelona, Spain Booth 278
June 1 - 5, 2008 American Society for Mass Spectrometry Denver, CO Booth 180
June 2 - 4, 2008 American Society for Microbiology Boston, MA Booth 1419
Thursday, June 5 @ 5:20 Novel Assay and Screening Technologies Label-Free HTS of Intractable Targets with Rapid-Fire Mass Spectrometry GTC - Grow Transform Connect Can "Jon" Ozbal, Vice President & General Manager, Rapid Fire Products
VIEW ALL EVENTS
RapidFire™ TechnologyRapidFire™ technology uses ultra high throughput mass spectrometry to enable label-free, high-throughput analysis of pharmaceutical compounds.
OpenArray™ Real-Time qPCRProvides researchers with a platform for performing thousands of qPCR assays across the entire human genome or on just a few selected genes.
RapidFire™ Lead DiscoveryUtilizes mass spectrometer detection at unprecedented speeds for label-free high throughput screening of targets that are not compatible with traditional assays.
©2008 BioTrove, Inc. All Rights Reserved.
